Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial.

医学 减肥 耐受性 临床试验 随机对照试验 人口 肥胖 内科学 气球 外科 不利影响
作者
Barham K Abu Dayyeh,Daniel B Maselli,Babusai Rapaka,Thomas Lavin,Mark Noar,Hisham Hussan,Christopher G Chapman,Violeta Popov,Pichamol Jirapinyo,Andres Acosta,Eric J Vargas,Andrew C Storm,Fateh Bazerbachi,Marvin Ryou,Matthew French,Sabrena Noria,Daniel Molina,Christopher C Thompson
出处
期刊:The Lancet [Elsevier]
卷期号:398 (10315): 1965-1973 被引量:7
标识
DOI:10.1016/s0140-6736(21)02394-1
摘要

Intragastric balloons are anatomy-preserving, minimally invasive obesity therapies. Enhanced tolerance and durability could help broaden clinical adoption. We investigated the safety and efficacy of an adjustable intragastric balloon (aIGB) in adults with obesity.In this prospective, multicentre, open-label, randomised clinical trial done at seven US sites, adults aged 22-65 years with obesity were randomly assigned (2:1) to aIGB with lifestyle intervention or lifestyle intervention alone (control) for 32 weeks. Balloon volume could be increased to facilitate weight loss or decreased for tolerability. Coprimary endpoints included mean percentage total bodyweight loss and responder rate (≥5% total bodyweight loss) at 32 weeks. We used a multiple imputed intention-to-treat population analysis. This study was registered with ClinicalTrials.gov, NCT02812160.Between Aug 9, 2016, and Dec 7, 2018, we randomly assigned 288 patients to aIGB (n=187 [65%]) or control (n=101 [35%]) groups. Mean total bodyweight loss at 32 weeks was 15·0% (95% CI 13·9-16·1) in the aIGB group versus 3·3% (2·0-4·6) in the control group (p<0·0001). Clinical response was observed in 171 (92%) patients in the aIGB group. Adjustments to the aIGB occurred in 145 (80%) patients for weight loss plateau or intolerance. Upward volume adjustment facilitated an additional mean 5·2% (4·5-5·8) total bodyweight loss. Downward volume adjustment allowed 21 (75%) patients in the aIGB group to complete the full duration of therapy. Intolerance caused early removal of the device in 31 (17%) patients. No micronutrient deficiencies were observed in the aIGB cohort. Device-related serious adverse events were observed in seven (4%) patients, without any deaths.When aIGB was combined with lifestyle modification, significant weight loss was achieved and maintained for 6 months following removal. Balloon volume adjustability permitted individualised therapy, maximising weight loss and tolerance.Spatz Medical.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
小透明发布了新的文献求助30
刚刚
orixero应助单纯的柚子采纳,获得10
1秒前
镜中人发布了新的文献求助10
3秒前
7秒前
二一完成签到 ,获得积分10
7秒前
7秒前
8秒前
8秒前
踌躇满志完成签到 ,获得积分10
9秒前
Criminology34举报王hu求助涉嫌违规
9秒前
10秒前
Akim应助xiaoleeyu采纳,获得10
11秒前
11秒前
帅气翠霜发布了新的文献求助10
12秒前
12秒前
13秒前
赖氨酸完成签到,获得积分10
13秒前
14秒前
qazcy发布了新的文献求助10
14秒前
迷路冰双发布了新的文献求助10
14秒前
沈海发布了新的文献求助10
15秒前
NexusExplorer应助喔喔采纳,获得10
16秒前
16秒前
zzx发布了新的文献求助10
17秒前
17秒前
安诺发布了新的文献求助10
19秒前
静好发布了新的文献求助10
19秒前
19秒前
ding应助无敌脉冲黄桃采纳,获得10
20秒前
21秒前
xiaoleeyu发布了新的文献求助10
22秒前
义气的青枫完成签到 ,获得积分10
22秒前
迷路冰双完成签到,获得积分10
23秒前
23秒前
MG发布了新的文献求助10
23秒前
xiaoqingnian完成签到,获得积分10
23秒前
geats发布了新的文献求助10
23秒前
威武大将军完成签到,获得积分10
24秒前
共享精神应助parpate采纳,获得10
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Kinesiophobia : a new view of chronic pain behavior 2000
Research for Social Workers 1000
Mastering New Drug Applications: A Step-by-Step Guide (Mastering the FDA Approval Process Book 1) 800
The Social Psychology of Citizenship 600
Signals, Systems, and Signal Processing 510
Discrete-Time Signals and Systems 510
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5912364
求助须知:如何正确求助?哪些是违规求助? 6832857
关于积分的说明 15785769
捐赠科研通 5037464
什么是DOI,文献DOI怎么找? 2711695
邀请新用户注册赠送积分活动 1662085
关于科研通互助平台的介绍 1603981